Aclarion, Inc. (ACON) - Q2 2026 10-Q Summary
Business Context and Reporting Period
Aclarion, Inc. is a healthcare technology company utilizing magnetic resonance spectroscopy (MRS) to optimize clinical treatments via its Nociscan reports. The company is classified as an emerging growth company and a smaller reporting company. This summary covers the quarterly period ended June 30, 2026, and the six-month period ended on the same date.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $25,208 | $19,319 | $46,348 | $38,309 |
| Gross Profit | $8,297 | $5,140 | $12,047 | $651 |
| Gross Margin | 32.9% | 26.6% | 26.0% | 1.7% |
| Net Loss | $(2,747,551) | $(1,600,757) | $(5,601,126) | $(3,638,193) |
| Diluted EPS | $(1.12) | $(2.75) | $(2.44) | $(9.09) |
| Cash & Equivalents | $16,285,462 (as of June 30, 2026) | |||
| Total Liabilities | $1,036,934 (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 30.5% quarter-over-quarter and 21.0% year-to-date, driven by higher volumes of Nociscan reports in the UK market following local coverage decisions.
- Operating Expenses: Total operating expenses rose significantly. Sales and marketing expenses increased 155.2% QoQ (driven by new hires and the CLARITY clinical trial) and 176.3% YTD. General and administrative expenses increased 53.8% QoQ, largely due to higher legal fees, investor relations costs, and Delaware franchise taxes.
- Cost of Revenue: While Q2 costs rose 19.3% with revenue, YTD costs decreased 8.9% despite higher revenue, improving the YTD gross margin from 1.7% to 26.0% due to operating efficiencies.
- One-Time Items: The prior year (2025) included a $672,500 penalty/settlement expense and a $73,272 gain on debt extinguishment, neither of which occurred in the current period.
- Capital Structure: The company completed a registered direct offering in January 2026 raising approximately $10.4 million. As of June 30, 2026, 420,121 pre-funded warrants remained outstanding (subsequently exercised in full post-period).
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash resources ($16.3 million) are sufficient to fund operations into the second half of 2027. No additional financing is currently required, though future needs may arise.
- Strategic Initiatives: The company is expanding sales teams in the US and UK and continuing enrollment in the CLARITY clinical trial, which is expected to increase sales and marketing expenses through 2026. Development of the Nociscan 3.0 product is ongoing.
- Equity Actions: In June 2026, the company granted 499,000 Restricted Stock Units (RSUs) to employees and directors. A stockholder rights agreement (poison pill) was adopted in March 2026, expiring March 2027. A $2.5 million share repurchase program was approved in April 2026, with no shares purchased as of June 30.
- Risks: Key risks include the need for future capital, dependence on reimbursement approvals, competition, and the inherent uncertainties of clinical trial outcomes. The company remains an emerging growth company with reduced disclosure obligations.
Investor Verification Checklist
- Revenue Sustainability: Verify the durability of the UK market growth and the timeline for US insurance payer adoption.
- Burn Rate vs. Runway: Confirm the $16.3 million cash balance against the projected operating burn rate, noting the significant increase in sales and marketing spend.
- Dilution Impact: Assess the impact of the 499,000 RSUs granted in June 2026 and the recent exercise of pre-funded warrants on future earnings per share.
- Regulatory Progress: Monitor the enrollment and results of the CLARITY clinical trial, which is a primary driver of current marketing expenses.
- Franchise Tax: Review the methodology for the increased Delaware franchise tax expense ($317k YTD vs $19k prior year) to ensure it is not a recurring anomaly.